Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 15 | SFEBES2008 | Next issue

Society for Endocrinology BES 2008

Oral Communications

Tumours, diabetes, bone

ea0015oc17 | Tumours, diabetes, bone | SFEBES2008

Cinacalcet is an effective and well tolerated treatment for MEN1 associated primary hyperparathyroidism

Moyes Veronica , Alexandraki Krystallenia , Monson John , Akker Scott , Chew Shern

Cinacalcet is a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism and parathyroid carcinoma. Multiple endocrine neoplasia type 1 (MEN1) patients may benefit considerably from cinacalcet. Affected patients have hyperplasia of multiple parathyroid glands, rather than a single resectable adenoma. Surgical cure requires removal of all parathyroid tissue, which is often unsuccessful, resulting in multiple neck explorations and hypoparathyroidism. Cinaca...

ea0015oc18 | Tumours, diabetes, bone | SFEBES2008

Human omental adipose tissue as a key site for the inflammatory 15-lipoxygenase pathway: Implications for metabolic disease

Hill Margaret J , McTernan Philip G , da Silva Nancy F , McGee Kirsty C , Kusminski Christine M , Baker Adam R , Kumar Sudhesh , Harte Alison L

Materials and methods: Paired AbSc and Om AT were collected from patients undergoing elective liposuction surgery (Age; 45±1.72 years; lean BMI; 22.91±0.56 kg/m2; obese BMI; 33.51±1.04 kg/m2; n=23) for gene expression analysis by microarray and real time polymerase chain reaction (PCR). Fasted blood was taken to measure metabolic parameters.Results: Microarray data showed that Om AT had signi...

ea0015oc19 | Tumours, diabetes, bone | SFEBES2008

Expression of the parathyroid-specific transcription factor glial cell-missing B is regulated by GATA3

Grigorieva Irina , Nesbit M Andrew , Ali Asif , Stechman Michael J , Thakker Rajesh

Glial-cell missing b (GCMB) is a parathyroid-specific gene whose loss results in parathyroid agenesis while haploinsufficiency of GATA3, which belongs to a family (GATA1-6) of dual zinc-finger transcription factors causes the hypoparathyroidism-deafness-renal dysplasia (HDR) syndrome. We investigated the possibility that GATA3 regulates GCMB expression. Our bioinformatics analysis revealed 5 putative GATA3 binding sites in the 1.3 kb region upstream of exon 1 of GCMB...

ea0015oc20 | Tumours, diabetes, bone | SFEBES2008

Serum 18 hydroxycortisol identifies aldosteronoma in the differential diagnosis of primary aldosteronism

Narasimhan Sowmya , McGregor Alan , Miell John , Chambers Susan Mary , Abraha (Daines) Hagosa Demoz , Aylwin Simon

Introduction: 18-hydroxycortisol (18-OHF) is known to be elevated in glucocorticoid remediable aldosteronism but there are few data relating to 18-OHF in the differential diagnosis of primary aldosteronism.Aim: We evaluated the usefulness of lying and standing 18-OHF in patients with primary aldosteronism in differentiating between aldosteronoma, bilateral adrenal hyperplasia (BAH) and normality.Methods: Patients (n=27) with...

ea0015oc21 | Tumours, diabetes, bone | SFEBES2008

Delineating the mechanisms of Visfatin regulation in human AT and the implications of TZD treatment in Type 2 Diabetes

McGee Kirsty , Harte Alison , da Silva Nancy , Creely Steven , Baker Adam , Kusminski Christine , Khanolkar Manish , Evans Marc , Chittari Madhu , Patel Vinod , Boardman Shirine , Kumar Sudhesh , McTernan Philip

Objective: The adipocytokine visfatin, expressed in abdominal adipose tissue (AT) is thought to mimic insulin activity. However, whilst central adiposity is closely related to insulin resistance (IR) and T2DM, visfatins’ role in the development of these conditions remains unclear.Method: We investigated circulating visfatin levels in non-diabetic (ND) and diabetic (T2DM) subjects and in T2DM patients pre- and post- rosiglitazone (RSG) treatment. We ...

ea0015oc22 | Tumours, diabetes, bone | SFEBES2008

Cataracts are a phenotypic feature of autosomal dominant hypocalcaemia with hypercalciuria (ADHH): lessons from the Nuf mouse model with an activating calcium sensing receptor (CaSR) mutation

Hannan Fadil , Curley Alan , Christie Paul , Harding Brian , Nesbit M Andrew , Cheeseman Michael , Bron Anthony , Thakker Rajesh

Activating mutations of the calcium sensing receptor (CaSR) result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH), in which patients may also suffer from polyuria, polydipsia, nephrocalcinosis, renal impairment, and ectopic calcification. A mouse model, Nuf, with an activating Leu723Gln CaSR mutation has been reported to develop the features of ADHH as well as cataracts that consist of dot nuclear opacities, which have not been described in ADHH patients...

ea0015oc23 | Tumours, diabetes, bone | SFEBES2008

Obesity resulting from Gsα mutations in the maternal (but not paternal) allele is a consequence of Gsα imprinting in the central nervous system

Chen Min , Dickerson Kathryn , Wang Jie , Kelleher James , Gavrilova Oksana , Zhang Qing-Hong , Xie Tao , Weinstein Lee

Gsα is a ubiquitously expressed G protein α-subunit that couples receptors to adenylyl cyclase and cAMP generation. In patients with Albright hereditary osteodystrophy (AHO), heterozygous Gsα mutations only lead to obesity when present on the maternal allele. Similarly, mice with heterozygous germline Gsα mutations on the maternal allele develop severe obesity and insulin resistance with reduced energy expenditure relative t...

ea0015oc24 | Tumours, diabetes, bone | SFEBES2008

The calcilytic agent NPS2143 rectifies hypocalcaemia in a mouse model, Nuf, that is due to an activating calcium-sensing-receptor (CaSR) mutation: relevance to autosomal dominant hypocalcaemia with hypercalciuria

Hannan Fadil , Walls Gerard , Kallay Eniko , Nesbit M Andrew , Hough Tertius , Cox Roger , Hu Jianxin , Spiegel Allen , Thakker Rajesh

The G-protein coupled calcium-sensing-receptor (CaSR) regulates calcium homeostasis and inactivating mutations result in familial hypocalciuric hypercalcaemia (FHH), whilst activating mutations result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH). Allosteric CaSR modulators consist of: calcimimetics, which activate the CaSR e.g. Cinacalcet, that is used to treat the hypercalcaemia of chronic renal failure and metastatic parathyroid carcinoma; and calcilytics e...